Subsequent Events (Details) (USD $) In Millions, except Per Share data, unless otherwise specified		0 Months Ended		0 Months Ended						0 Months Ended			0 Months Ended
	Sep. 16, 2014 Auxilium Pharmaceuticals, Inc. [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc. [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc. [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc. [Member] Subsequent Event [Member] QLT, Inc. [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc. [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc. [Member] Subsequent Event [Member] Maximum [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc., Consideration Option One [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc., Consideration Option Two [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc., Consideration Option Two [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc., Consideration Option Three [Member] Subsequent Event [Member]	Oct. 09, 2014 Auxilium Pharmaceuticals, Inc., Consideration Option Three [Member] Subsequent Event [Member]	Sep. 30, 2014 Litha Healthcare Group Limited [Member] Paladin Labs Inc. [Member]	Oct. 16, 2014 Litha Healthcare Group Limited [Member] Subsequent Event [Member] Paladin Labs Inc. [Member]	Oct. 16, 2014 Litha Healthcare Group Limited [Member] Subsequent Event [Member] Paladin Labs Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, share price (in dollars per share)			$ 33.25						$ 33.25		$ 16.625			$ 0.25
Business combination, expected consideration		$ 2,900.0											$ 40.9
Business acquisition, share price premium, percent	55.00%
Business combination, consideration, equity, percent						75.00%	100.00%
Business combination, consideration, equity, ratio							0.488			0.244
Business combination, consideration, cash, percent						50.00%		100.00%
Business combination, termination fee		$ 70.0		$ 28.4	$ 150.0
Percentage of equity method of investments in subsidiaries												70.00%